Brief: Amyris Achieves Promising In-Vivo Results For Intranasal Delivery Of Rna/Nlc Vaccinepr Newswire
20/08/2021 13:06
Aug 20 (Reuters) - Amyris Inc AMRS.O :
* AMYRIS ACHIEVES PROMISING IN-VIVO RESULTS FOR INTRANASAL
DELIVERY OF RNA/NLC VACCINEPR NEWSWIRE
* AMYRIS INC - IF APPROVED AND COMMERCIALIZED, AMYRIS/IDRI
RNA
VACCINE IS TARGETED TO BE MORE ACCESSIBLE TO PEOPLE IN
UNDERSERVED COUNTRIES
* AMYRIS INC - IN-VIVO RESULTS INDICATE THAT, AMYRIS/IDRI
RNA
VACCINE GENERATES ANTIBODIES AND PROVIDES UPPER RESPIRATORY
PROTECTION FOR SARS-COV-2
Source text for Eikon: ID:nPn9R6lHTa
Further company coverage: AMRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amyris
See all newsBrief: Amyris Announces Kathy Fortmann As New CEO
Brief: Amyris Announced Termination Or Separation Of About 80 Employees on Feb 7
Brief: Amyris- Related To Sale Of Some Consumer Brands, Announces Termination/ Separation Of About 220 Employees
Brief: Amyris On December 12, Debtors Entered Into An Amendment To And Restatement Of That Certain Plan Support Agreement, Dated October 12, 2023
Brief: Amyris Inc On August 10, Received Notice Of Delisting From Nasdaq